TY - JOUR
T1 - Weight gain on androgen deprivation therapy
T2 - Which patients are at highest risk?
AU - Seible, Daniel M.
AU - Gu, Xiangmei
AU - Hyatt, Andrew S.
AU - Beard, Clair J.
AU - Choueiri, Toni K.
AU - Efstathiou, Jason A.
AU - Miyamoto, David T.
AU - Mitin, Timur
AU - Martin, Neil E.
AU - Sweeney, Christopher J.
AU - Trinh, Quoc Dien
AU - Beckman, Joshua A.
AU - Basaria, Shehzad
AU - Nguyen, Paul L.
N1 - Funding Information:
Funding Support: This work is supported by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, and a grant from an Anonymous Family Foundation.
PY - 2014/6
Y1 - 2014/6
N2 - Objective To identify factors associated with weight gain at 1 year from initiation of androgen deprivation therapy (ADT). Methods A retrospective review assessed weight change among 118 men with nonmetastatic prostate cancer treated with ADT for at least 6 months. Outcome associations were tested using 2-tailed t tests and linear regression. Results Men in our cohort had significant weight gain (+1.32 kg, P =.0005) in the 1 year after ADT initiation. Three risk factors for weight gain on ADT were identified as follows: age <65 years (2.72 kg gained, P =.001), body mass index (BMI) <30 (1.98 kg gained, P =.00002), and nondiabetic status (1.56 kg gained, P =.0003). Multivariable regression found both age <65 years (beta = 4.01, P =.02) and BMI <30 (beta = 3.57, P =.03) to be independently predictive of weight gain, whereas nondiabetic status was nonsignificantly predictive of weight gain (beta = 2.14, P =.29). Weight change was further stratified by the total number of risk factors present (risk score): scores of 0, 1, 2, and 3 risk factors corresponded to weight changes of -1.10, +0.41, +1.34, and +3.79 kg, respectively (P-trend =.0005). Conclusion Age <65 years and BMI <30 were both independently associated with weight gain 1 year after starting ADT. Increasing weight gain was also strongly associated with increasing number of baseline risk factors present. Despite traditional concerns about ADT in unhealthy men, these data suggest younger, healthier patients may be at higher risk for gaining weight on ADT and should be counseled accordingly.
AB - Objective To identify factors associated with weight gain at 1 year from initiation of androgen deprivation therapy (ADT). Methods A retrospective review assessed weight change among 118 men with nonmetastatic prostate cancer treated with ADT for at least 6 months. Outcome associations were tested using 2-tailed t tests and linear regression. Results Men in our cohort had significant weight gain (+1.32 kg, P =.0005) in the 1 year after ADT initiation. Three risk factors for weight gain on ADT were identified as follows: age <65 years (2.72 kg gained, P =.001), body mass index (BMI) <30 (1.98 kg gained, P =.00002), and nondiabetic status (1.56 kg gained, P =.0003). Multivariable regression found both age <65 years (beta = 4.01, P =.02) and BMI <30 (beta = 3.57, P =.03) to be independently predictive of weight gain, whereas nondiabetic status was nonsignificantly predictive of weight gain (beta = 2.14, P =.29). Weight change was further stratified by the total number of risk factors present (risk score): scores of 0, 1, 2, and 3 risk factors corresponded to weight changes of -1.10, +0.41, +1.34, and +3.79 kg, respectively (P-trend =.0005). Conclusion Age <65 years and BMI <30 were both independently associated with weight gain 1 year after starting ADT. Increasing weight gain was also strongly associated with increasing number of baseline risk factors present. Despite traditional concerns about ADT in unhealthy men, these data suggest younger, healthier patients may be at higher risk for gaining weight on ADT and should be counseled accordingly.
UR - http://www.scopus.com/inward/record.url?scp=84901620436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901620436&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2014.02.006
DO - 10.1016/j.urology.2014.02.006
M3 - Article
C2 - 24726149
AN - SCOPUS:84901620436
SN - 0090-4295
VL - 83
SP - 1316
EP - 1321
JO - Urology
JF - Urology
IS - 6
ER -